Executive vice president and worldwide chairman, pharmaceuticals,
Johnson & Johnson
Taubert took over Johnson & Johnson’s $40 billion pharmaceutical business in 2018. The service line accounts about half of the company’s revenue. In early November, J&J joined with three other companies to reach a $26 billion settlement with counties and cities that sued them for damages related to the opioid epidemic. J&J officials have said they expect to have their single-shot coronavirus vaccine ready for approval by February. During a third-quarter earnings call, Taubert said the company plans to work with local partners to reach out to minority communities.